Medical treatment of diabetic retinopathy with somatostatin analogues

Stela S. Palii, Sergio Caballero, Gideon Shapiro, Maria B. Grant

Research output: Contribution to journalReview article

25 Scopus citations


Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number1
StatePublished - Jan 1 2007


  • Diabetic retinopathy
  • Neovascularisation
  • Octreotide
  • Somatostatin analogues
  • Somatostatin receptor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Medical treatment of diabetic retinopathy with somatostatin analogues'. Together they form a unique fingerprint.

  • Cite this